203 related articles for article (PubMed ID: 25272944)
1. Cardioprotective effects of low-dose combination therapy with rosuvastatin and fasudil in the isolated rat heart.
Wu N; Li W; Lv Y; Shu W; Jia D
Pharmazie; 2014 Sep; 69(9):704-8. PubMed ID: 25272944
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Rho-kinase by fasudil restores the cardioprotection of ischemic postconditioninng in hypercholesterolemic rat heart.
Wu N; Li W; Shu W; Lv Y; Jia D
Mol Med Rep; 2014 Nov; 10(5):2517-24. PubMed ID: 25231456
[TBL] [Abstract][Full Text] [Related]
3. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium.
Hamid SA; Bower HS; Baxter GF
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2598-606. PubMed ID: 17220176
[TBL] [Abstract][Full Text] [Related]
4. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
Jones SP; Gibson MF; Rimmer DM; Gibson TM; Sharp BR; Lefer DJ
J Am Coll Cardiol; 2002 Sep; 40(6):1172-8. PubMed ID: 12354446
[TBL] [Abstract][Full Text] [Related]
5. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
Weinberg EO; Scherrer-Crosbie M; Picard MH; Nasseri BA; MacGillivray C; Gannon J; Lian Q; Bloch KD; Lee RT
Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1802-9. PubMed ID: 15563531
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts.
Di Napoli P; Taccardi AA; Grilli A; De Lutiis MA; Barsotti A; Felaco M; De Caterina R
Cardiovasc Res; 2005 Jun; 66(3):462-71. PubMed ID: 15914111
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
Bulhak A; Roy J; Hedin U; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of ligustrazine against myocardial ischaemia reperfusion in rats: the role of endothelial nitric oxide synthase.
Lv L; Jiang SS; Xu J; Gong JB; Cheng Y
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):20-7. PubMed ID: 22004361
[TBL] [Abstract][Full Text] [Related]
10. Effect of combined treatment with rosuvastatin and protein kinase Cβ2 inhibitor on angiogenesis following myocardial infarction in diabetic rats.
Huang D; Wang FB; Guo M; Li S; Yan ML; Yu T; Wei M; Li JB
Int J Mol Med; 2015 Mar; 35(3):829-38. PubMed ID: 25524396
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats.
Ikeda Y; Young LH; Lefer AM
J Cardiovasc Pharmacol; 2003 Apr; 41(4):649-56. PubMed ID: 12658068
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosuvastatin on ADMA, rhokinase, NADPH oxidase, caveolin-1, hsp 90 and NFkB levels in a rat model of myocardial ischaemia-reperfusion.
Burma O; Onat E; Uysal A; Ilhan N; Erol D; Ozcan M; Sahna E
Cardiovasc J Afr; 2014; 25(5):212-6. PubMed ID: 25629537
[TBL] [Abstract][Full Text] [Related]
13. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
Bulhak AA; Gourine AV; Gonon AT; Sjöquist PO; Valen G; Pernow J
Acta Physiol Scand; 2005 Feb; 183(2):151-9. PubMed ID: 15676056
[TBL] [Abstract][Full Text] [Related]
14. [Rosuvastatin enhances the protective effects of ischemic postconditioning on myocardial ischaemia-reperfusion injury in type 2 diabetic rat].
CAI W; FANG J; CHEN ZY; LIN YL; WU LM; CHEN LL
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Sep; 38(9):814-8. PubMed ID: 21092651
[TBL] [Abstract][Full Text] [Related]
15. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
Matsuo S; Saiki Y; Adachi O; Kawamoto S; Fukushige S; Horii A; Saiki Y
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):902-9. PubMed ID: 25454916
[TBL] [Abstract][Full Text] [Related]
16. High‑dose fasudil preconditioning and postconditioning attenuate myocardial ischemia‑reperfusion injury in hypercholesterolemic rats.
Wu N; Zhang X; Jia D
Mol Med Rep; 2014 Feb; 9(2):560-6. PubMed ID: 24271017
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury.
Ke D; Fang J; Fan L; Chen Z; Chen L
Coron Artery Dis; 2013 Jun; 24(4):334-41. PubMed ID: 23531479
[TBL] [Abstract][Full Text] [Related]
18. The methyl ester of rosuvastatin elicited an endothelium-independent and 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent relaxant effect in rat aorta.
López-Canales JS; López-Sanchez P; Perez-Alvarez VM; Wens-Flores I; Polanco AC; Castillo-Henkel E; Castillo-Henkel C
Braz J Med Biol Res; 2011 May; 44(5):438-44. PubMed ID: 21445535
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of rosuvastatin on aortic adverse remodeling in nitric oxide-deficient rats.
Neto-Ferreira R; Novaes Rocha V; da Silva Torres T; Mandarim-de-Lacerda CA; de Carvalho JJ
Exp Toxicol Pathol; 2011 Jul; 63(5):473-8. PubMed ID: 20537513
[TBL] [Abstract][Full Text] [Related]
20. The protective effect of fasudil pretreatment combined with ischemia postconditioning on myocardial ischemia/reperfusion injury in rats.
Li WN; Wu N; Shu WQ; Guan YE; Jia DL
Eur Rev Med Pharmacol Sci; 2014; 18(18):2748-58. PubMed ID: 25317813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
